Alcon Inc.
https://www.alcon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alcon Inc.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Alcaftadine Eye Drops For Allergies Available OTC In US With Allergan’s Lastacaft Launch
Abbvie business starts sales of Lastacaft (alcaftadine solution/0.25%) eye drops, licensed from innovator Vistakon Pharmaceuticals, approved through an sNDA. Full switch removes Lastacaft from Rx sales in US.
The Top 10 Medtech Themes For 2022 – And M&A Trends
The operating environment for medical technology companies becomes more complex, competitive and costly every year. There is no expectation that 2022 will buck that trend, even as the medtech sector prepares for a third year of working under conditions shaped by the COVID-19 pandemic.
Exec Chat: Alcon Seeks Vision ‘Utopia’ For Cataract Surgery Patients
Jeannette Bankes, the general manager of Alcon’s global surgical business, talked to Medtech Insight about how the company is addressing the cataract surgery market with a range of intraocular lenses intended to return the patients vision to as close to its natural optimal function as possible.
Company Information
- Industry
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
Medical Devices
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Alcon Laboratories, Inc.
- Alcon Universal SA
- Ivantis, Inc.